Monday, January 23, 2017

Shark Compound Could Treat Parkinson

Squalamine, a chemical compound found in the body of the dogfish shark was potentially reduce the formation of toxic protein associated with the development of Parkinson's disease. The latest research is published in Proceedings of the National Academy of Sciences.

Squalamine stop the buildup and the toxicity of the protein alpha-synuclein (a-synuclein) in the model bracelet from disease and human nerve cells. Parkinson's is a progressive condition that is characterized by tremors, movement problems body, extremity stiffness, and balance problems are also coordinating body.

One million people in the US living with Parkinson's per year. The cause of Parkinson's so far unclear. Recent research has shown the buildup of a-synuclein in the brain play a role in disease development. Clumps of a-synuclein caused the death of brain cells.

Researchers then hunt for compounds that can block the coagulation, thereby helping to treat or prevent disease. Co-author, Dr. Michael Zasloff who is also professor of surgery and pediatrics at Georgetown University School of Medicine in Washington said squalamine be the most potent drug ingredients.

Squalamine is a compound derived from dogfish shark tissue that protects nerve cells from toxic human a-synuclein due to be antimicrobial. This compound was first discovered Dr. Zasloff in the early 1990s.

Researchers conducted a series of in vitro experiments to see squalamine interaction with a-synuclein and lipid vesicles. The team found these compounds to stop clots by preventing a protein that binds to the vesicle becomes negatively charged Lipil where the a-synuclein normally formed.

The team examined the squalamine in the roundworm Caenorhabditis elegans. This is because this worm has at least 40 percent of the same genes with humans, so that it can be the ideal model for testing human diseases. Researchers then modify the worm that paralyzed like Parkinson's in humans.

"We really see that squalamine prevent the development of a-synuclein and stop muscle paralysis in worms," ​​said Zasloff, quoted by Medical News Today recently. Researchers believe that the overall potential of the study. They are developing further studies to test the compounds directly to human patients suffering from Parkinson's.

No comments: